Flu Vaccine 2026/2027: Options, Pre-Order & Guidelines

February 12, 2026 Dr. Michael Lee – Health Editor Health

German healthcare providers are preparing for the 2026/2027 influenza season with updated guidance on vaccine selection and pre-ordering procedures, according to recent communications from the regional health authorities of Baden-Württemberg (KVbawue) and the German Society for Senior Medicine (DSTG).

For individuals aged 60 and over, healthcare professionals can choose between two influenza vaccines: Efluelda®, a high-dose vaccine, and Fluad®, which utilizes an MF59 adjuvant to enhance the immune response. The Standing Committee on Vaccination (STIKO) has, since October 2024, recommended the use of an MF59-adjuvanted vaccine in addition to the high-dose option for this age group.

The KVbawue has announced a pre-order quota of up to 115 percent compared to the influenza vaccinations administered during the 2024/2025 season, applying to both patients over 60 and those under 60. This quota aims to ensure sufficient vaccine supply for the upcoming season.

Vaccination procedures will remain consistent with current practices. Patients aged 60 and over, as well as those with medical or occupational indications, will receive vaccines through the standard healthcare benefit (Sprechstundenbedarf). Patients under 60 without specific medical or occupational needs will continue to receive vaccines on a limited basis through the Sprechstundenbedarf system.

Authorities are emphasizing strict adherence to prescription protocols. Healthcare providers are instructed to prescribe influenza vaccines exclusively through the Sprechstundenbedarf system, avoiding individual patient names on prescriptions to prevent potential reimbursement issues from health insurance funds.

The German Paul-Ehrlich-Institut (PEI) provides updated information on the availability of influenza vaccines and maintains a list of authorized preparations, though it notes that the list does not guarantee current market availability.

Recent changes to the German protection vaccination guideline, based on a new recommendation from the STIKO in October 2024, now consider Fluad Tetra® and Efluelda® as equally effective in protecting individuals aged 60 and over against influenza. Previously, Efluelda® was the preferred option, with Fluad® used only when Efluelda® was unavailable.